Additionally, the 36-month beta value for SANA is 1.35. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for SANA is 121.63M and currently, short sellers hold a 28.19% ratio of that float. The average trading volume of SANA on November 13, 2024 was 1.37M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SANA) stock’s latest price update
Sana Biotechnology Inc (NASDAQ: SANA)’s stock price has plunge by -1.73relation to previous closing price of 2.89. Nevertheless, the company has seen a -16.22% plunge in its stock price over the last five trading sessions. accesswire.com reported 2024-11-12 that NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. (“Sana Biotechnology, Inc.”) (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it “will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs”.
SANA’s Market Performance
SANA’s stock has fallen by -16.22% in the past week, with a monthly drop of -29.18% and a quarterly drop of -40.21%. The volatility ratio for the week is 9.50% while the volatility levels for the last 30 days are 7.79% for Sana Biotechnology Inc The simple moving average for the last 20 days is -21.79% for SANA stock, with a simple moving average of -56.57% for the last 200 days.
Analysts’ Opinion of SANA
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see SANA reach a price target of $16. The rating they have provided for SANA stocks is “Buy” according to the report published on June 26th, 2024.
H.C. Wainwright gave a rating of “Buy” to SANA, setting the target price at $12 in the report published on January 16th of the current year.
SANA Trading at -30.53% from the 50-Day Moving Average
After a stumble in the market that brought SANA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.33% of loss for the given period.
Volatility was left at 7.79%, however, over the last 30 days, the volatility rate increased by 9.50%, as shares sank -31.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.29% lower at present.
During the last 5 trading sessions, SANA fell by -16.22%, which changed the moving average for the period of 200-days by -52.51% in comparison to the 20-day moving average, which settled at $3.63. In addition, Sana Biotechnology Inc saw -30.39% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SANA starting from NATHAN HARDY, who proposed sale 45,796 shares at the price of $3.95 back on Oct 21 ’24. After this action, NATHAN HARDY now owns shares of Sana Biotechnology Inc, valued at $180,807 using the latest closing price.
Mulligan Richard, the Director of Sana Biotechnology Inc, sale 150,000 shares at $4.08 during a trade that took place back on Sep 24 ’24, which means that Mulligan Richard is holding 2,848,121 shares at $612,570 based on the most recent closing price.
Stock Fundamentals for SANA
The total capital return value is set at -0.58. Equity return is now at value -92.90, with -51.36 for asset returns.
Based on Sana Biotechnology Inc (SANA), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -2.37.
Currently, EBITDA for the company is -252.39 million with net debt to EBITDA at 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.47.
Conclusion
In conclusion, Sana Biotechnology Inc (SANA) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
